Adaptimmune Therapeutics Plc Quick Ratio (ADAP) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)

Adaptimmune Therapeutics Plc's Quick Ratio

ADAP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 0.51 a new company low.

Within Biotechnology & Pharmaceuticals industry 120 other companies have achieved higher Quick Ratio than Adaptimmune Therapeutics Plc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 1036 to 1949.

Explain Quick Ratio?
How much Cash & cash equivalents ADAP´s has?
What are ADAP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADAP Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -37.24 % -23.1 % -11.35 % -15.56 % 7.81 %
Y / Y Cash & cash equivalent Change -87.87 % -65.02 % 3.18 % -25.35 % 4.93 %
Quick Ratio MRQ 0.51 0.98 2.35 1.9 2.62
ADAP's Total Ranking # 1949 # 1036 # 897 # 820 # 651
Seq. Current Liabilities Change 0.86 % -20.85 % 1.69 % -22.68 % 23.58 %
Seq. Cash & cash equivalent Change -48.13 % -66.86 % 25.57 % -43.79 % 49.52 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 121
Healthcare Sector # 654
Overall Market # 1949


Quick Ratio Statistics
High Average Low
50.24 6.8 0.51
(Dec 31 2018)   (Jun 30 2025)




Financial Statements
Adaptimmune Therapeutics Plc's Current Liabilities $ 52 Millions Visit ADAP's Balance sheet
Adaptimmune Therapeutics Plc's Cash & cash equivalent $ 26 Millions Visit ADAP's Balance sheet
Source of ADAP's Sales Visit ADAP's Sales by Geography


Cumulative Adaptimmune Therapeutics Plc's Quick Ratio

ADAP's Quick Ratio for the trailling 12 Months

ADAP Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -22.21 % -10.1 % -3.9 % 1.91 % 9.65 %
Y / Y Cash & cash equivalent TTM Growth -47.74 % -18.21 % -7.09 % -15 % -13.87 %
Quick Ratio TTM 1.51 2.06 2.28 2.2 2.25
Total Ranking TTM # 2984 # 3143 # 2845 # 3170 # 3107
Seq. Current Liabilities TTM Growth -11.7 % -5.55 % -2.9 % -3.94 % 2.05 %
Seq. Cash & cash equivalent TTM Growth -35.12 % -14.81 % 0.75 % -6.14 % 1.53 %

Quick ratio ranking by company, industry and sector >> Back to ADAP Financial Strength Comparisons >> Go to Compare ADAP Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ADAP's Current Liabilities to $51.51 millions, cumulative Quick Ratio to 1.51 below the ADAP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Adaptimmune Therapeutics Plc. While Quick Ratio overall ranking has improved so far to 2984, from total ranking during the twelve months ending first quarter 2025 at 3143.

Explain Quick Ratio?
How much Cash & cash equivalents ADAP´s has?
What are ADAP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 820
Within the Market # 2984


trailing twelve months Quick Ratio Statistics
High Average Low
10.46 4.68 1.84
(Mar 31 2021)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Palisade Bio Inc   1.36 $ 5.417  Millions$ 3.970  Millions
Dyadic International Inc   1.36 $ 4.983  Millions$ 3.662  Millions
Adma Biologics Inc   1.23 $ 90.285  Millions$ 73.671  Millions
Alvotech  1.16 $ 151.452  Millions$ 130.308  Millions
Bioatla Inc   1.15 $ 18.207  Millions$ 15.795  Millions
Intensity Therapeutics Inc   1.02 $ 2.216  Millions$ 2.164  Millions
Calidi Biotherapeutics Inc   0.99 $ 5.279  Millions$ 5.353  Millions
Bio techne Corp  0.91 $ 162.186  Millions$ 179.178  Millions
Coherus Oncology inc   0.90 $ 237.637  Millions$ 263.629  Millions
Cognition Therapeutics inc   0.87 $ 10.743  Millions$ 12.364  Millions
Phoenix Biotech Acquisition Corp  0.86 $ 6.531  Millions$ 7.618  Millions
Sangamo Therapeutics Inc   0.80 $ 38.344  Millions$ 47.659  Millions
Invivyd Inc   0.79 $ 34.905  Millions$ 44.451  Millions
ADAPTIN BIO, INC.  0.78 $ 1.352  Millions$ 1.740  Millions
Innate Pharma Sa  0.77 $ 31.463  Millions$ 41.047  Millions
Protalix Biotherapeutics inc   0.74 $ 17.895  Millions$ 24.091  Millions
Pluri Inc   0.64 $ 20.613  Millions$ 32.328  Millions
Valneva Se  0.63 $ 122.808  Millions$ 193.672  Millions
Meiragtx Holdings Plc  0.60 $ 32.166  Millions$ 53.436  Millions
Scinai Immunotherapeutics Ltd  0.57 $ 0.989  Millions$ 1.750  Millions
Curis Inc   0.56 $ 10.138  Millions$ 18.107  Millions
Sab Biotherapeutics Inc   0.54 $ 5.714  Millions$ 10.677  Millions
Dbv Technologies S a   0.53 $ 29.371  Millions$ 55.647  Millions
Adaptimmune Therapeutics Plc  0.51 $ 26.061  Millions$ 51.513  Millions
Halozyme Therapeutics Inc   0.46 $ 61.861  Millions$ 134.282  Millions
Cellectis S a   0.41 $ 59.809  Millions$ 145.458  Millions
Amgen Inc   0.39 $ 8,028.000  Millions$ 20,476.000  Millions
Outlook Therapeutics Inc   0.28 $ 8.901  Millions$ 31.432  Millions
Biocardia Inc   0.27 $ 0.980  Millions$ 3.642  Millions
Elutia Inc   0.25 $ 8.500  Millions$ 33.548  Millions

Date modified: 2026-09-26T07:28:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.